Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2024-05-16 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of the final patient visit for their GNC-501 clinical trial regarding post-COVID treatment. It provides updates on the trial status, methodology, and expected timeline for results. This type of corporate announcement regarding clinical trial progress and operational milestones falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into specific financial reporting or governance categories.
2024-05-16 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of the 'last patient last visit' for a clinical trial (GNC-501). It provides updates on the trial's progress, methodology, and expected timeline for top-line results. As this is a general corporate announcement regarding operational/clinical progress that does not fit into specific financial reporting categories like earnings releases or annual reports, it is classified as a regulatory filing/announcement.
2024-05-16 English
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that GeNeuro has made its '2023 Universal Registration Document' available to the public. It provides a link to the website where the report can be downloaded and mentions that the document was filed with the Autorité des marchés financiers. Per the 'Menu vs Meal' rule, since this is a short announcement (1919 characters) stating that a report has been published/made available, it is classified as a Report Publication Announcement (RPA).
2024-05-02 French
Terms of availability of a registration document or its updates
Report Publication Announcement Classification · 1% confidence The document is a short press release (3384 characters) that announces the publication and filing of the company's 2023 Universal Registration Document with the AMF. It provides a link to the company's website to access the actual report. Per the 'Menu vs Meal' rule, this is an announcement of a report, not the report itself, and therefore qualifies as a Report Publication Announcement (RPA).
2024-05-02 English
2023 Universal Registration Document
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-04-30 English
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is a press release titled 'GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update'. It contains key financial highlights, including a consolidated income statement for the year ended December 31, 2023, and management's discussion of financial results and business outlook. While it contains financial data, it is structured as a press release (Earnings Release) rather than a full statutory Annual Report (10-K). It provides the initial announcement of the annual results, which fits the definition of an Earnings Release (ER). FY 2023
2024-04-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.